A phase II clinical study of mAMSA in small cell carcinoma of the lung

Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppression. No responses were observed. Median survival from the start of treatment with mAMSA was 5 weeks.